NASDAQ:ARVNArvinas Stock Price, Forecast & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARVN shares have decreased by 22.9% and is now trading at $33.95. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.01. The business earned $6.24 million during the quarter, compared to the consensus estimate of $5.18 million. Arvinas had a negative return on equity of 30.74% and a negative net margin of 171.74%. View Arvinas' earnings history.

11 brokers have issued 12 month price targets for Arvinas' stock. Their forecasts range from $38.00 to $75.00. On average, they expect Arvinas' share price to reach $57.10 in the next year. This suggests a possible upside of 68.2% from the stock's current price. View analysts' price targets for Arvinas.

News coverage about ARVN stock has been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arvinas earned a news impact score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Arvinas.

Arvinas saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,300,000 shares, an increase of 13.8% from the June 15th total of 2,900,000 shares. Based on an average trading volume of 608,400 shares, the short-interest ratio is currently 5.4 days. Approximately 12.9% of the shares of the company are short sold. View Arvinas' Current Options Chain.

Some companies that are related to Arvinas include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Legend Biotech (LEGN), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), Biohaven Pharmaceutical (BHVN), Global Blood Therapeutics (GBT), Evotec (EVTCY) and Amicus Therapeutics (FOLD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), ImmunoGen (IMGN), Krystal Biotech (KRYS), Protalix Biotherapeutics (PLX), Senseonics (SENS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Vaxart (VXRT).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $33.95.

Arvinas has a market capitalization of $1.33 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]